Form 4: Inovio Pharmaceuticals Director Roger D. Dansey Reports Stock Option and Restricted Stock Unit Grant

Director Roger D. Dansey reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Summary

• On May 21, 2024, Roger D. Dansey, a director of Inovio Pharmaceuticals, reported the acquisition of 2,917 common stock options and 2,167 restricted stock units (RSUs).
• The options have an exercise price of $10.99 and vest 100% on May 21, 2025, expiring on May 21, 2034.
• The RSUs also vest 100% on May 21, 2025, and each unit represents a contingent right to receive one share of common stock.
• These grants were made under the 2023 Omnibus Incentive Plan, following the issuer's non-employee director compensation policy.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard compensation practice. The grant itself is neither overwhelmingly positive nor negative.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing performance and value creation.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The grant of equity to a director can align their interests with shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates